Though far from the first large drugmaker to strike a pricing deal with the Trump administration, AbbVie’s new accord is ...
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to ...
Jan 12 (Reuters) - AbbVie said on Monday that it has struck a three-year deal with U.S. President Donald Trump's ...
Look into AbbVie's strategy a company built around its blockbuster Humira, now diversifying its pipeline after the patent ...
Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...
SPRINGFIELD, Mass. (WWLP) – Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of ...
AbbVie ABBV stock has risen 8.0% in six months, adding more than $24 billion to its market value. AbbVie has successfully navigated the loss of exclusivity (“LOE”) of its blockbuster drug, Humira, by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results